Cancer Drug Coverage Parity Act of 2015

Appropriations for NCI, CDC Ovarian Cancer Programs, OCRP at CDMRP, Regulations for Laboratory Developed Tests, passage of Cancer Drug Parity Act HR 2739/S 1566.

Client expense: Not reported · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE

HR 2739 / S 1566, the Cancer Drug Coverage Parity Act of 2015 - insurance coverage equality for oral anticancer medications

Client expense: $42,005 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 2739 / S 1566, the Cancer Drug Coverage Parity Act of 2015 - insurance coverage equality for oral anticancer medications

Client expense: $45,703 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 2739 and S. 1566 Cancer Drug Coverage Parity Act

Client expense: $45,703 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 2739 / S 1566, the Cancer Drug Coverage Parity Act of 2015 - insurance coverage equality for oral anticancer medications

Client expense: $45,703 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 524 Comprehensive Addiction and Recovery Act of 2016 Senate HELP Committee Innovations Package HR 6 21st Century Cures Act HR 1600 Patients Access to Treatment Act of 2015 HR 2739/S 1566 Cancer Drug Coverage Parity Act HR 3381/S 1883 Childhood Cancer STAR Act HR 3119 Palliative Care Hospice Education and Training Act S 2141 Transparent Ratings on Usability and Security to Transform Information Technology (TRUST IT) Act of 2015 H.R. 2846 Planning Actively for Cancer Treatment (PACT) Act of 2015 S. 2511 Improving Health Information Technology Act Reforms to the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act

Client expense: $65,519 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Policy and implementation issues relating to Public Law No. 111-148, the Patient Protection and Affordable Care Act. Policy and implementation issues relating to Public Law No. 112-144, the Food and Drug Administration Safety and Innovation Act, specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the Food and Drug Administration Amendments Act, specifically FDA's Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy. H.R. 34, the 21st Century Cures Act. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 2841, the Fair Access for Safe and Timely Generics Act. H.R. 1600, the Patients Access to Treatments Act. H.R. 2739, the Cancer Drug Coverage Parity Act. S. 1566, the Cancer Drug Coverage Parity Act. H.R. 3982, the Family Cord Blood Banking Act.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6); Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues; Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).

Client expense: $740,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 30, Save American Workers Act (Young) - definition of full-time employee H.R. 117, Reclaiming Individual Liberty Act (Garrett) - ACA individual mandate H.R. 221, ACA Taxpayer Bailout Prevention Act (Harris) - risk corridors program H.R. 371, Care for All Act (Fortenberry) - catastrophic plans H.R. 494, Competitive Health Insurance Reform Act (Gosar) - antitrust policy H.R. 543, Health Care Choice Act (Blackburn) - national marketplace for individual health insurance H.R. 724, Taxpayer Bailout Protection Act (Lance) - risk corridors program H.R. 815, Access to Independent Health Insurance Advisors Act (Long-Schrader) - treatment of broker compensation in MLR calculation H.R. 954, CO-OP Consumer Protection Act (Smith) - exemption from individual mandate H.R. 1770, Data Security and Breach Notification Act (Blackburn-Welch) - data security H.R. 2205, Data Security Act (Neugebauer) - data security H.R. 2739, Cancer Drug Coverage Parity Act (Lance) - coverage of oral anti-cancer drugs H.R. 2868, Small Business Health Fairness Act (Johnson) - association health plans H.R. 3323, Dental and Optometric Care Access Act (Carter) - dental and vision benefits H.R. 3727, Health Insurance Rate Review Act (Schakowsky) - rate review H.R. 4299, Patient Opportunity Protection Act (Blum) - HIPAA excepted benefits H.R. 5410, Health Coverage State Flexibility Act (Flores) - grace period for recipients of advanced premium tax credits H.R. 5589, Plan Verification and Fairness Act (Blackburn) - pre-enrollment verification process H.R. 5921, State Age Rating Flexibility Act (Bucshon) - age rating flexibility H.R. 6019, Relief from Obamacare Mandate Act (Young) - exemption from individual mandate H.R. 6049, Protection from Insurance Exchange Monopolies Act (Heck) - exemption from individual mandate H.R. 5926, FY 2017 Labor-HHS-Education Appropriations Bill (Cole) - ACA risk corridors provision, HHS appropriations H. Res. 887, Public Option (DeFazio) S. 30, Forty Hours Is Full Time Act (Collins) - definition of full-time employee S. 123, ACA Taxpayer Bailout Prevention Act (Rubio) - risk corridors program S. 158, Employee Health Care Protection Act (Cassidy) - grandfathering of health coverage S. 359, Taxpayer Bailout Protection Act (Cassidy) - risk corridors program S. 1099, Protecting Affordable Coverage for Employees Act (Scott-Shaheen) - ACA definition of small employer S. 1532, Affordability is Access Act (Murray) - coverage of OTC birth control S. 1566, Cancer Drug Coverage Parity Act (Kirk) - coverage of oral anti-cancer drugs S. 1661, Access to Independent Health Insurance Advisors Act (Isakson-Coons) - treatment of broker compensation in MLR calculation S. 2172, Health Insurance Rate Review Act (Feinstein) - rate review S. 2803, Taxpayers Before Insurers Act (Sasse) - ACA reinsurance program S. 3296, Protection from ObamaCare Monopolies Act (McCain) - exemption from individual mandate S. 3297, Relief from Obamacare Mandate Act (Cotton) - exemption from individual mandate S. 3326, State Flexibility to Provide Affordable Health Options Act (Alexander) - ACA subsidies, exemption from individual mandate S. Res. 561, Public Option (Merkley) Regulatory Issues: Insurance regulatory reform; issues related to the coordination of private and public disability income benefits; disability risk management; disability income insurance enrollment and awareness; issues related to encouraging impaired workers to stay in/return to the workforce; issues relating to the coordination of benefits between private health insurance plans and Medicaid; Medigap claims processing and crossover fees; Medigap cross-over claim issues, Medigap coverage, implementation of Medigap standardized plan offerings; Medigap carrier recoveries related to CMS fraud and abuse enforcement activities, and issues related to Medigap educational materials, and other Medigap issues; fraud and abuse issues affecting public and private insurance coverage; issues relating to antitrust; implementation of the Mental Health Parity Act requirements; summary of benefits and coverage disclosures; pre-existing condition insurance plans; accountable care organizations; coverage of preventive services; preexisting condition exclusions; lifetime and annual dollar limits on benefits; patient protections; grandfathered health plan provisions; dependent coverage; treatment of expatriate plans; compliance with the transitional reinsurance program; issues related to fraud, waste, abuse, Stark/Anti-Kickback laws and regulations, non-discriminatory wellness programs; issues related to supplemental products; issues related to implementation of the Telephone Consumer Protection Act; issues relating to third party payment of premiums; and other issues relating to health care reform implementation.

Client expense: $1,330,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Office of Personnel Management (OPM), SENATE, Treasury, Dept of, White House Office

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

Client expense: $510,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

General FDA issues; S 1566/HR 2739 Cancer Drug Coverage Parity Act; S 3056 CREATES Act; HR 2841 FAST Generics Act. 21st Century Cures legislation (HR6/HR 34)

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to health disparities, health care reform, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including: H.R.3119 & S.2748, the Palliative Care and Hospice Education and Training Act; H.R.716 & S.370, the Breast Density & Mammography Reporting Act; H.R.3381 & S.1883, Childhood Cancer STAR Act; and regulations relating to tanning beds. In addition, regulatory issues before the FDA relating to laboratory developed tests, and any legislation pertaining thereto, suncreens, colorectal cancer screening tests, electronic medical devices, H.R.2739/S.1566 - the Cancer Drug Coverage Parity Act, H.R.2846 - Planning Actively for Cancer Treatment Act, S.1014 - Personal Care Products Safety Act, H.R.1608 - Lymphedema Treatment Act, H.R.2191/S.1170 - the Breast Cancer Research Stamp Reauthorization Act, S.705 - Transportation Alternatives Act, S.540 - School Food Modernization Act, and H.R.644 - America Gives More Act, CDC opioid prescription guidelines, and legislation relating to opioid prescribing, addition and rehabilitation; H.R.5475, the Health Equity and Accountability Act; S.2787, the SAME Act and Senate Amendment 4369 to S.2943, the Senate Defense Authorization bill; and S.3136, H.R.5003 childhood nutrition bill; and H.R.2017 and S.2217, the Common Sense Nutrition Disclosure Act; and S.524 and H.R.953, the Comprehensive Addiction and Recovery Act, and related bills and amendments, S.3077, the Marijuana Effective Drug Studies Act of 2016.

Client expense: $1,620,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), White House Office

Issues relating to health disparities, health care reform, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including: H.R.3119 & S.2748, the Palliative Care and Hospice Education and Training Act; H.R.716 & S.370, the Breast Density & Mammography Reporting Act; H.R.3381 & S.1883, Childhood Cancer STAR Act; and regulations relating to tanning beds. In addition, regulatory issues before the FDA relating to laboratory developed tests, and any legislation pertaining thereto, suncreens, colorectal cancer screening tests, electronic medical devices, H.R.2739/S.1566 - the Cancer Drug Coverage Parity Act, H.R.2846 - Planning Actively for Cancer Treatment Act, S.1014 - Personal Care Products Safety Act, H.R.1608 - Lymphedema Treatment Act, H.R.2191/S.1170 - the Breast Cancer Research Stamp Reauthorization Act, S.705 - Transportation Alternatives Act, S.540 - School Food Modernization Act, and H.R.644 - America Gives More Act, CDC opioid prescription guidelines, and legislation relating to opioid prescribing, addition and rehabilitation; H.R.5475, the Health Equity and Accountability Act; S.2787, the SAME Act and Senate Amendment 4369 to S.2943, the Senate Defense Authorization bill; and S.3136, H.R.5003 childhood nutrition bill; and H.R.2017 and S.2217, the Common Sense Nutrition Disclosure Act; and S.524 and H.R.953, the Comprehensive Addiction and Recovery Act, and related bills and amendments, S.3077, the Marijuana Effective Drug Studies Act of 2016.

Client expense: $1,630,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), White House Office

Patients' Access to Treatments Act (HR 1600); Cancer Drug Coverage Parity Act (HR 2739, S 1566); 21st Century Cures Act (HR 6); Issues related to patient protections and the Affordable Care Act; Andrea Sloan Compassionate Use Reform & Enhancement Act (HR 909); White House Moonshot Cancer Initiative

Client expense: $70,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Office of the Vice President of the United States, SENATE

Patients' Access to Treatments Act (H.R. 1600) Cancer Drug Coverage Parity Act (S. 1566/H.R. 2739) Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2015 (H.R. 1807) Advancing Hope Act (H.R. 1537/S. 1878) Implementation of Health Reform Legislation/Patient Protection and Affordable Care Act (P.L. 111-148) Hematology and Oncology Drug Research and Approval Issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical Trials Regulations and Coverage 21st Century Cures Act (H.R. 6, H.R. 34) Innovation for Healthier Americans initiative Issues impacting coverage for hematologic diseases and conditions

Client expense: $30,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of the Vice President of the United States, SENATE, Veterans Affairs, Dept of (VA)

S. 1566/HR 2739 - Cancer Drug Coverage Parity Act; 21st Century Cures Act.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 1566/HR 2739 - Cancer Drug Coverage Parity Act.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to blood cancer research diagnosis, treatment and cures, including coverage and reimbursement of cancer treatment therapies. Issues related to H. R. 6, 21st Century Cures Act and the Senate Innovation for Healthier Americans Initiative. H. R. 2739, S. 1596, the Cancer Drug Coverage Parity Act. Outreach regarding the "National Cancer Moonshot" initiative. Education and outreach regarding the FDA's Acute Myeloid Leukemia (AML) Master Trial. Issues related to patient protections and the Affordable Care Act.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Biosimilars - naming (FDA); precision medicine initiative; ACA implementation; clinical trials issues (FDA); HR 2739/S 1566 - Cancer Drug Coverage Parity Act

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 4959: Ensuring Access to General Surgery Act of 2016 H.R. 105: Quality Health Care Coalition Act of 2015 H.R. 3309: Flex-IT 2 Act H.R. 647: Access to Life-Saving Trauma Care for All Americans Act H.R. 648: Trauma Systems and Regionalization of Emergency Care Reauthorization Act H.R. 836: Health Care Safety Net Enhancement Act of 2015 H.R. 865: Good Samaritan Health Professionals Act of 2015 S. 3101: Good Samaritan Health Professionals Act of 2016 H.R. 1934: Cancer Care Payment Reform Act of 2015 S. 2943/H.R.1735: National Defense Authorization Act (NDAA) H.R.4909 - National Defense Authorization Act for Fiscal Year 2017 H.R. 2739: Cancer Drug Coverage Parity Act of 2015 S. 624/H.R. 1220: Removing Barriers to Colorectal Cancer Screening Act of 2015 S. 3166: Ensuring Access to General Surgery Act of 2016 S. 3522: Graduate Medical Education Equity Act H.R. 1925: To award a Congressional Gold Medal to Dr. Balazs "Ernie" Bodai in recognition of his many outstanding contributions to the Nation, including a tireless commitment to breast cancer research. H.Res. 487: Recognizing the importance of cancer program accreditation in ensuring comprehensive, high quality, patient-centered cancer care Veterans Access, Choice and Accountability Act Concurrent Surgery MACRA Proposed Rule Implementation GME Health Professional Shortage Areas (HPSAs) Health Information Technology (Health IT) Chronic Care Coordination 96-Hour Rule Bleeding Control for the Injured (Stop The Bleed campaign) Opioids Cancer/Appropriations Medicare Part B Merit-Based Incentive Payment System (MIPS) & Alternative Payment Models (APMs) Qualified Clinical Data Registry (QCDR) reporting mechanism Physician Quality Reporting System (PQRS) Video Recording Surgery RAC Audits Energy and Commerce Concussion Initiative Data Use Protection Legislation FOIA Energy and Commerce Pediatric Trauma Caucus Responsible Data Transparency Act

Client expense: $18,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE, Veterans Affairs, Dept of (VA)

H.R. 4959: Ensuring Access to General Surgery Act of 2016 H.R. 105: Quality Health Care Coalition Act of 2015 H.R. 3309: Flex-IT 2 Act H.R. 647: Access to Life-Saving Trauma Care for All Americans Act H.R. 648: Trauma Systems and Regionalization of Emergency Care Reauthorization Act H.R. 836: Health Care Safety Net Enhancement Act of 2015 H.R. 865: Good Samaritan Health Professionals Act of 2015 S. 3101: Good Samaritan Health Professionals Act of 2016 H.R. 1934: Cancer Care Payment Reform Act of 2015 S. 2943/H.R.1735: National Defense Authorization Act (NDAA) H.R.4909 - National Defense Authorization Act for Fiscal Year 2017 H.R. 2739: Cancer Drug Coverage Parity Act of 2015 S. 624/H.R. 1220: Removing Barriers to Colorectal Cancer Screening Act of 2015 S. 3166: Ensuring Access to General Surgery Act of 2016 S. 3522: Graduate Medical Education Equity Act H.R. 1925: To award a Congressional Gold Medal to Dr. Balazs "Ernie" Bodai in recognition of his many outstanding contributions to the Nation, including a tireless commitment to breast cancer research. H.Res. 487: Recognizing the importance of cancer program accreditation in ensuring comprehensive, high quality, patient-centered cancer care Veterans Access, Choice and Accountability Act Concurrent Surgery MACRA Proposed Rule Implementation GME Health Professional Shortage Areas (HPSAs) Health Information Technology (Health IT) Chronic Care Coordination 96-Hour Rule Bleeding Control for the Injured (Stop The Bleed campaign) Opioids Cancer/Appropriations Medicare Part B Merit-Based Incentive Payment System (MIPS) & Alternative Payment Models (APMs) Qualified Clinical Data Registry (QCDR) reporting mechanism Physician Quality Reporting System (PQRS) Video Recording Surgery RAC Audits Energy and Commerce Concussion Initiative Data Use Protection Legislation FOIA Energy and Commerce Pediatric Trauma Caucus Responsible Data Transparency Act

Client expense: $18,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE, Veterans Affairs, Dept of (VA)

H.R. 4959: Ensuring Access to General Surgery Act of 2016 H.R. 105: Quality Health Care Coalition Act of 2015 H.R. 3309: Flex-IT 2 Act H.R. 647: Access to Life-Saving Trauma Care for All Americans Act H.R. 648: Trauma Systems and Regionalization of Emergency Care Reauthorization Act H.R. 836: Health Care Safety Net Enhancement Act of 2015 H.R. 865: Good Samaritan Health Professionals Act of 2015 S. 3101: Good Samaritan Health Professionals Act of 2016 H.R. 1934: Cancer Care Payment Reform Act of 2015 S. 2943/H.R.1735: National Defense Authorization Act (NDAA) H.R.4909 - National Defense Authorization Act for Fiscal Year 2017 H.R. 2739: Cancer Drug Coverage Parity Act of 2015 S. 624/H.R. 1220: Removing Barriers to Colorectal Cancer Screening Act of 2015 S. 3166: Ensuring Access to General Surgery Act of 2016 S. 3522: Graduate Medical Education Equity Act H.R. 1925: To award a Congressional Gold Medal to Dr. Balazs "Ernie" Bodai in recognition of his many outstanding contributions to the Nation, including a tireless commitment to breast cancer research. H.Res. 487: Recognizing the importance of cancer program accreditation in ensuring comprehensive, high quality, patient-centered cancer care Veterans Access, Choice and Accountability Act Concurrent Surgery MACRA Proposed Rule Implementation GME Health Professional Shortage Areas (HPSAs) Health Information Technology (Health IT) Chronic Care Coordination 96-Hour Rule Bleeding Control for the Injured (Stop The Bleed campaign) Opioids Cancer/Appropriations Medicare Part B Merit-Based Incentive Payment System (MIPS) & Alternative Payment Models (APMs) Qualified Clinical Data Registry (QCDR) reporting mechanism Physician Quality Reporting System (PQRS) Video Recording Surgery RAC Audits Energy and Commerce Concussion Initiative Data Use Protection Legislation FOIA Energy and Commerce Pediatric Trauma Caucus Responsible Data Transparency Act

Client expense: $168,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE, Veterans Affairs, Dept of (VA)

H.R. 4959: Ensuring Access to General Surgery Act of 2016 H.R. 105: Quality Health Care Coalition Act of 2015 H.R. 3309: Flex-IT 2 Act H.R. 647: Access to Life-Saving Trauma Care for All Americans Act H.R. 648: Trauma Systems and Regionalization of Emergency Care Reauthorization Act H.R. 836: Health Care Safety Net Enhancement Act of 2015 H.R. 865: Good Samaritan Health Professionals Act of 2015 S. 3101: Good Samaritan Health Professionals Act of 2016 H.R. 1934: Cancer Care Payment Reform Act of 2015 S. 2943/H.R.1735: National Defense Authorization Act (NDAA) H.R.4909 - National Defense Authorization Act for Fiscal Year 2017 H.R. 2739: Cancer Drug Coverage Parity Act of 2015 S. 624/H.R. 1220: Removing Barriers to Colorectal Cancer Screening Act of 2015 S. 3166: Ensuring Access to General Surgery Act of 2016 S. 3522: Graduate Medical Education Equity Act H.R. 1925: To award a Congressional Gold Medal to Dr. Balazs "Ernie" Bodai in recognition of his many outstanding contributions to the Nation, including a tireless commitment to breast cancer research. H.Res. 487: Recognizing the importance of cancer program accreditation in ensuring comprehensive, high quality, patient-centered cancer care Veterans Access, Choice and Accountability Act Concurrent Surgery MACRA Proposed Rule Implementation GME Health Professional Shortage Areas (HPSAs) Health Information Technology (Health IT) Chronic Care Coordination 96-Hour Rule Bleeding Control for the Injured (Stop The Bleed campaign) Opioids Cancer/Appropriations Medicare Part B Merit-Based Incentive Payment System (MIPS) & Alternative Payment Models (APMs) Qualified Clinical Data Registry (QCDR) reporting mechanism Physician Quality Reporting System (PQRS) Video Recording Surgery RAC Audits Energy and Commerce Concussion Initiative Data Use Protection Legislation FOIA Energy and Commerce Pediatric Trauma Caucus Responsible Data Transparency Act

Client expense: $168,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE, Veterans Affairs, Dept of (VA)

HR 1600, Patient Access to Treatment Act; HR 2739 Cancer Drug Coverage Parity Act/S. 1566 Cancer Drug Coverage Parity Act

Client expense: Not reported · Firm income: $30,000

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

Client expense: $740,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

Client expense: $820,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Cancer Drug Coverage Parity Act (H.R. 2739/S. 1655)

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 524 Comprehensive Addiction and Recovery Act of 2016 Senate HELP Committee Innovations Package HR 6 21st Century Cures Act HR 1600 Patients Access to Treatment Act of 2015 HR 2739/S 1566 Cancer Drug Coverage Parity Act HR 3381/S 1883 Childhood Cancer STAR Act HR 3119 Palliative Care Hospice Education and Training Act S 2141 Transparent Ratings on Usability and Security to Transform Information Technology (TRUST IT) Act of 2015 H.R. 2846 Planning Actively for Cancer Treatment (PACT) Act of 2015 S. 2511 Improving Health Information Technology Act Reforms to the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act

Client expense: $169,982 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to health disparities, health care reform, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including: H.R.3119 & S.2748, the Palliative Care and Hospice Education and Training Act; H.R.716 & S.370, the Breast Density & Mammography Reporting Act; H.R.3381 & S.1883, Childhood Cancer STAR Act; and regulations relating to tanning beds. In addition, regulatory issues before the FDA relating to laboratory developed tests, and any legislation pertaining thereto, suncreens, colorectal cancer screening tests, electronic medical devices, H.R.2739/S.1566 - the Cancer Drug Coverage Parity Act, H.R.2846 - Planning Actively for Cancer Treatment Act, S.1014 - Personal Care Products Safety Act, H.R.1608 - Lymphedema Treatment Act, H.R.2191/S.1170 - the Breast Cancer Research Stamp Reauthorization Act, S.705 - Transportation Alternatives Act, S.540 - School Food Modernization Act, and H.R.644 - America Gives More Act, CDC opioid prescription guidelines, and legislation relating to opioid prescribing, addition and rehabilitation; H.R.5475, the Health Equity and Accountability Act; S.2787, the SAME Act and Senate Amendment 4369 to S.2943, the Senate Defense Authorization bill; and S.3136, H.R.5003 childhood nutrition bill; and H.R.2017 and S.2217, the Common Sense Nutrition Disclosure Act; and S.524 and H.R.953, the Comprehensive Addiction and Recovery Act, and related bills and amendments, S.3077, the Marijuana Effective Drug Studies Act of 2016.

Client expense: $1,200,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), White House Office

H.R. 30, Save American Workers Act (Young) - definition of full-time employee H.R. 117, Reclaiming Individual Liberty Act (Garrett) - ACA individual mandate H.R. 221, ACA Taxpayer Bailout Prevention Act (Harris) - risk corridors program H.R. 371, Care for All Act (Fortenberry) - catastrophic plans H.R. 494, Competitive Health Insurance Reform Act (Gosar) - antitrust policy H.R. 543, Health Care Choice Act (Blackburn) - national marketplace for individual health insurance H.R. 724, Taxpayer Bailout Protection Act (Lance) - risk corridors program H.R. 815, Access to Independent Health Insurance Advisors Act (Long-Schrader) - treatment of broker compensation in MLR calculation H.R. 954, CO-OP Consumer Protection Act (Smith) - exemption from individual mandate H.R. 1770, Data Security and Breach Notification Act (Blackburn-Welch) - data security H.R. 2205, Data Security Act (Neugebauer) - data security H.R. 2739, Cancer Drug Coverage Parity Act (Lance) - coverage of oral anti-cancer drugs H.R. 2868, Small Business Health Fairness Act (Johnson) - association health plans H.R. 3323, Dental and Optometric Care Access Act (Carter) - dental and vision benefits H.R. 3727, Health Insurance Rate Review Act (Schakowsky) - rate review H.R. 4299, Patient Opportunity Protection Act (Blum) - HIPAA excepted benefits H.R. 5410, Health Coverage State Flexibility Act (Flores) - grace period for recipients of advanced premium tax credits H.R. 5485, Financial Services and General Government Appropriations Act (Crenshaw) - risk corridors amendment H.R. 5589, Plan Verification and Fairness Act (Blackburn) - pre-enrollment verification process H.R. 5921, State Age Rating Flexibility Act (Bucshon) - age rating flexibility H.R. 6019, Relief from Obamacare Mandate Act (Young) - exemption from individual mandate H.R. 6049, Protection from Insurance Exchange Monopolies Act (Heck) - exemption from individual mandate H.R. 5926, FY 2017 Labor-HHS-Education Appropriations Bill (Cole) - ACA risk corridors provision, HHS appropriations H. Res. 887, Public Option (DeFazio) S. 30, Forty Hours Is Full Time Act (Collins) - definition of full-time employee S. 123, ACA Taxpayer Bailout Prevention Act (Rubio) - risk corridors program S. 158, Employee Health Care Protection Act (Cassidy) - grandfathering of health coverage S. 359, Taxpayer Bailout Protection Act (Cassidy) - risk corridors program S. 1099, Protecting Affordable Coverage for Employees Act (Scott-Shaheen) - ACA definition of small employer S. 1532, Affordability is Access Act (Murray) - coverage of OTC birth control S. 1566, Cancer Drug Coverage Parity Act (Kirk) - coverage of oral anti-cancer drugs S. 1661, Access to Independent Health Insurance Advisors Act (Isakson-Coons) - treatment of broker compensation in MLR calculation S. 2172, Health Insurance Rate Review Act (Feinstein) - rate review S. 2803, Taxpayers Before Insurers Act (Sasse) - ACA reinsurance program S. 3296, Protection from ObamaCare Monopolies Act (McCain) - exemption from individual mandate S. 3297, Relief from Obamacare Mandate Act (Cotton) - exemption from individual mandate S. 3326, State Flexibility to Provide Affordable Health Options Act (Alexander) - ACA subsidies, exemption from individual mandate S. Res. 561, Public Option (Merkley) Regulatory Issues: Insurance regulatory reform; issues related to the coordination of private and public disability income benefits; disability risk management; disability income insurance enrollment and awareness; issues related to encouraging impaired workers to stay in/return to the workforce; issues relating to the coordination of benefits between private health insurance plans and Medicaid; Medigap claims processing and crossover fees; Medigap cross-over claim issues, Medigap coverage, implementation of Medigap standardized plan offerings; Medigap carrier recoveries related to CMS fraud and abuse enforcement activities, and issues related to Medigap educational materials, and other Medigap issues; fraud and abuse issues affecting public and private insurance coverage; issues relating to antitrust; implementation of the Mental Health Parity Act requirements; summary of benefits and coverage disclosures; pre-existing condition insurance plans; accountable care organizations; coverage of preventive services; preexisting condition exclusions; lifetime and annual dollar limits on benefits; patient protections; grandfathered health plan provisions; dependent coverage; treatment of expatriate plans; compliance with the transitional reinsurance program; issues related to fraud, waste, abuse, Stark/Anti-Kickback laws and regulations, non-discriminatory wellness programs; issues related to supplemental products; issues related to implementation of the Telephone Consumer Protection Act; and other issues relating to health care reform implementation.

Client expense: $1,710,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office

Patients' Access to Treatments Act (HR 1600); Cancer Drug Coverage Parity Act (HR 2739, S 1566); 21st Century Cures Act (HR 6); PPACA Marketplace plan patient protections; Andrea Sloan Compassionate Use Reform & Enhancement Act (HR 909); Senate Innovation for Healthier Americans Initiative; White House Moonshot Cancer Initiative; FDA Appropriations

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Office of the Vice President of the United States, SENATE

Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6); Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues; Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).

Client expense: $420,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

General FDA issues; S 1566/HR 2739 Cancer Drug Coverage Parity Act; S 3056 CREATES Act; HR 2841 FAST Generics Act.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Policy and implementation issues relating to Public Law No. 111-148, the Patient Protection and Affordable Care Act. Policy and implementation issues relating to Public Law No. 112-144, the Food and Drug Administration Safety and Innovation Act, specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the Food and Drug Administration Amendments Act, specifically FDA's Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy. H.R. 6, the 21st Century Cures Act. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 2841, the Fair Access for Safe and Timely Generics Act. H.R. 1600, the Patients Access to Treatments Act. H.R. 2739, the Cancer Drug Coverage Parity Act. S. 1566, the Cancer Drug Coverage Parity Act. H.R. 3982, the Family Cord Blood Banking Act.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 4959: Ensuring Access to General Surgery Act of 2016 H.R. 105: Quality Health Care Coalition Act of 2015 H.R. 3309: Flex-IT 2 Act H.R. 647: Access to Life-Saving Trauma Care for All Americans Act H.R. 648: Trauma Systems and Regionalization of Emergency Care Reauthorization Act H.R. 836: Health Care Safety Net Enhancement Act of 2015 H.R. 865: Good Samaritan Health Professionals Act of 2015 S. 3101: Good Samaritan Health Professionals Act of 2016 H.R. 1934: Cancer Care Payment Reform Act of 2015 S. 2943/H.R.1735: National Defense Authorization Act (NDAA) H.R.4909 - National Defense Authorization Act for Fiscal Year 2017 H.R. 2739: Cancer Drug Coverage Parity Act of 2015 S. 624/H.R. 1220: Removing Barriers to Colorectal Cancer Screening Act of 2015 S. 3166: Ensuring Access to General Surgery Act of 2016 H.R. 1925: To award a Congressional Gold Medal to Dr. Balazs "Ernie" Bodai in recognition of his many outstanding contributions to the Nation, including a tireless commitment to breast cancer research. H.Res. 487: Recognizing the importance of cancer program accreditation in ensuring comprehensive, high quality, patient-centered cancer care Veterans Access, Choice and Accountability Act Concurrent Surgery MACRA Proposed Rule Implementation GME Health Professional Shortage Areas (HPSAs) Health Information Technology (Health IT) Chronic Care Coordination 96-Hour Rule Bleeding Control for the Injured (Stop The Bleed campaign) Opioids Cancer/Appropriations Medicare Part B Merit-Based Incentive Payment System (MIPS) & Alternative Payment Models (APMs) Qualified Clinical Data Registry (QCDR) reporting mechanism Physician Quality Reporting System (PQRS) Video Recording Surgery RAC Audits Energy and Commerce Concussion Initiative Data Use Protection Legislation FOIA Energy and Commerce Pediatric Trauma Caucus Responsible Data Transparency Act

Client expense: $30,154 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE, Veterans Affairs, Dept of (VA)

H.R. 4959: Ensuring Access to General Surgery Act of 2016 H.R. 105: Quality Health Care Coalition Act of 2015 H.R. 3309: Flex-IT 2 Act H.R. 647: Access to Life-Saving Trauma Care for All Americans Act H.R. 648: Trauma Systems and Regionalization of Emergency Care Reauthorization Act H.R. 836: Health Care Safety Net Enhancement Act of 2015 H.R. 865: Good Samaritan Health Professionals Act of 2015 S. 3101: Good Samaritan Health Professionals Act of 2016 H.R. 1934: Cancer Care Payment Reform Act of 2015 S. 2943/H.R.1735: National Defense Authorization Act (NDAA) H.R.4909 - National Defense Authorization Act for Fiscal Year 2017 H.R. 2739: Cancer Drug Coverage Parity Act of 2015 S. 624/H.R. 1220: Removing Barriers to Colorectal Cancer Screening Act of 2015 S. 3166: Ensuring Access to General Surgery Act of 2016 H.R. 1925: To award a Congressional Gold Medal to Dr. Balazs "Ernie" Bodai in recognition of his many outstanding contributions to the Nation, including a tireless commitment to breast cancer research. H.Res. 487: Recognizing the importance of cancer program accreditation in ensuring comprehensive, high quality, patient-centered cancer care Veterans Access, Choice and Accountability Act Concurrent Surgery MACRA Proposed Rule Implementation GME Health Professional Shortage Areas (HPSAs) Health Information Technology (Health IT) Chronic Care Coordination 96-Hour Rule Bleeding Control for the Injured (Stop The Bleed campaign) Opioids Cancer/Appropriations Medicare Part B Merit-Based Incentive Payment System (MIPS) & Alternative Payment Models (APMs) Qualified Clinical Data Registry (QCDR) reporting mechanism Physician Quality Reporting System (PQRS) Video Recording Surgery RAC Audits Energy and Commerce Concussion Initiative Data Use Protection Legislation FOIA Energy and Commerce Pediatric Trauma Caucus Responsible Data Transparency Act

Client expense: $30,154 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE, Veterans Affairs, Dept of (VA)

H.R. 4959: Ensuring Access to General Surgery Act of 2016 H.R. 105: Quality Health Care Coalition Act of 2015 H.R. 3309: Flex-IT 2 Act H.R. 647: Access to Life-Saving Trauma Care for All Americans Act H.R. 648: Trauma Systems and Regionalization of Emergency Care Reauthorization Act H.R. 836: Health Care Safety Net Enhancement Act of 2015 H.R. 865: Good Samaritan Health Professionals Act of 2015 S. 3101: Good Samaritan Health Professionals Act of 2016 H.R. 1934: Cancer Care Payment Reform Act of 2015 S. 2943/H.R.1735: National Defense Authorization Act (NDAA) H.R.4909 - National Defense Authorization Act for Fiscal Year 2017 H.R. 2739: Cancer Drug Coverage Parity Act of 2015 S. 624/H.R. 1220: Removing Barriers to Colorectal Cancer Screening Act of 2015 S. 3166: Ensuring Access to General Surgery Act of 2016 H.R. 1925: To award a Congressional Gold Medal to Dr. Balazs "Ernie" Bodai in recognition of his many outstanding contributions to the Nation, including a tireless commitment to breast cancer research. H.Res. 487: Recognizing the importance of cancer program accreditation in ensuring comprehensive, high quality, patient-centered cancer care Veterans Access, Choice and Accountability Act Concurrent Surgery MACRA Proposed Rule Implementation GME Health Professional Shortage Areas (HPSAs) Health Information Technology (Health IT) Chronic Care Coordination 96-Hour Rule Bleeding Control for the Injured (Stop The Bleed campaign) Opioids Cancer/Appropriations Medicare Part B Merit-Based Incentive Payment System (MIPS) & Alternative Payment Models (APMs) Qualified Clinical Data Registry (QCDR) reporting mechanism Physician Quality Reporting System (PQRS) Video Recording Surgery RAC Audits Energy and Commerce Concussion Initiative Data Use Protection Legislation FOIA Energy and Commerce Pediatric Trauma Caucus Responsible Data Transparency Act

Client expense: $184,615 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE, Veterans Affairs, Dept of (VA)

H.R. 4959: Ensuring Access to General Surgery Act of 2016 H.R. 105: Quality Health Care Coalition Act of 2015 H.R. 3309: Flex-IT 2 Act H.R. 647: Access to Life-Saving Trauma Care for All Americans Act H.R. 648: Trauma Systems and Regionalization of Emergency Care Reauthorization Act H.R. 836: Health Care Safety Net Enhancement Act of 2015 H.R. 865: Good Samaritan Health Professionals Act of 2015 S. 3101: Good Samaritan Health Professionals Act of 2016 H.R. 1934: Cancer Care Payment Reform Act of 2015 S. 2943/H.R.1735: National Defense Authorization Act (NDAA) H.R.4909 - National Defense Authorization Act for Fiscal Year 2017 H.R. 2739: Cancer Drug Coverage Parity Act of 2015 S. 624/H.R. 1220: Removing Barriers to Colorectal Cancer Screening Act of 2015 S. 3166: Ensuring Access to General Surgery Act of 2016 H.R. 1925: To award a Congressional Gold Medal to Dr. Balazs "Ernie" Bodai in recognition of his many outstanding contributions to the Nation, including a tireless commitment to breast cancer research. H.Res. 487: Recognizing the importance of cancer program accreditation in ensuring comprehensive, high quality, patient-centered cancer care Veterans Access, Choice and Accountability Act Concurrent Surgery MACRA Proposed Rule Implementation GME Health Professional Shortage Areas (HPSAs) Health Information Technology (Health IT) Chronic Care Coordination 96-Hour Rule Bleeding Control for the Injured (Stop The Bleed campaign) Opioids Cancer/Appropriations Medicare Part B Merit-Based Incentive Payment System (MIPS) & Alternative Payment Models (APMs) Qualified Clinical Data Registry (QCDR) reporting mechanism Physician Quality Reporting System (PQRS) Video Recording Surgery RAC Audits Energy and Commerce Concussion Initiative Data Use Protection Legislation FOIA Energy and Commerce Pediatric Trauma Caucus Responsible Data Transparency Act

Client expense: $184,615 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE, Veterans Affairs, Dept of (VA)

HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.

Client expense: $570,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to blood cancer research diagnosis, treatment and cures, including coverage and reimbursement of cancer treatment therapies. Issues related to H. R. 6, 21st Century Cures Act and the Senate Innovation for Healthier Americans Initiative. H. R. 2739, S. 1596, the Cancer Drug Coverage Parity Act. Outreach regarding the "National Cancer Moonshot" initiative.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patients' Access to Treatments Act (H.R. 1600) Cancer Drug Coverage Parity Act (S. 1566/H.R. 2739) Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2015 (H.R. 1807) Advancing Hope Act (H.R. 1537/S. 1878) Resolution expressing support for the designation of the month of September 2016 as "Sickle Cell Disease Awareness Month" (S.Res. 592/H.Res. 903) Implementation of Health Reform Legislation/Patient Protection and Affordable Care Act (P.L. 111-148) Hematology and Oncology Drug Research and Approval Issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical Trials Regulations and Coverage 21st Century Cures Act (H.R. 6) Innovation for Healthier Americans initiative Issues impacting coverage for hematologic diseases and conditions

Client expense: $30,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of the Vice President of the United States, SENATE, Veterans Affairs, Dept of (VA)

S. 1566/HR 2739 - Cancer Drug Coverage Parity Act; Cancer moonshot.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, Vice President of the U.S.

Biosimilars - naming (FDA); precision medicine initiative; ACA implementation; clinical trials issues (FDA); HR 2739/S 1566 - Cancer Drug Coverage Parity Act

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 1566/HR 2739 - Cancer Drug Coverage Parity Act.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES

HR 1600, Patient Access to Treatment Act; HR 2739 Cancer Drug Coverage Parity Act/S. 1566 Cancer Drug Coverage Parity Act

Client expense: Not reported · Firm income: $30,000

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE